{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:03:57Z","timestamp":1793361837077,"version":"4.5.0"},"reference-count":93,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Perivascular epithelioid cell tumors (PEComas) are rare mesenchymal neoplasms with distinct histopathological, immunophenotypic, and molecular features. Described in the early 1990s, they include angiomyolipoma, lymphangioleiomyomatosis, and clear cell \u201csugar\u201d tumors, and can arise in various sites, most often the kidney, uterus, lung, and soft tissues. While usually indolent, some exhibit aggressive behavior with invasion, recurrence, and metastasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive literature review was conducted to summarize the current understanding of PEComa biology, diagnostic approaches, risk stratification systems, and therapeutic strategies. Emphasis was placed on studies defining the molecular landscape, treatment outcomes with mTOR inhibitors, and emerging prognostic tools.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Molecularly, most PEComas harbor loss-of-function mutations in the TSC1 or TSC2 genes, resulting in constitutive mTOR signaling pathway activation, a central driver of tumorigenesis and a key therapeutic target. A distinct subset is defined by TFE3 gene rearrangements, exhibiting unique clinicopathologic features and suggesting an alternative, mTOR-independent oncogenic mechanism. Accurate diagnosis requires integration of morphology, immunohistochemistry, and molecular testing, while risk stratification is guided by established histologic criteria and emerging prognostic models. Surgical resection remains the standard of care for localized disease, whereas mTOR inhibitors constitute the cornerstone of systemic therapy for advanced or unresectable PEComas. Additional approaches, including immune checkpoint inhibitors, locoregional therapies, and chemotherapy, may be considered in selected cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This review summarizes PEComa biology, diagnosis, prognosis, and treatment, emphasizing the need for international collaboration to improve risk stratification and personalized therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag134","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T11:28:43Z","timestamp":1775561323000},"source":"Crossref","is-referenced-by-count":1,"title":["PEComas: current concepts in diagnosis, molecular pathways, and emerging treatments"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3540-4331","authenticated-orcid":false,"given":"Giada","family":"Del Baldo","sequence":"first","affiliation":[{"name":"Pediatric Hematology\/Oncology and Cell and Gene Therapy, IRCCS Bambino Ges\u00f9 Children\u2019s Hospital , Rome, 00165,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0250-6043","authenticated-orcid":false,"given":"Giuseppe Maria","family":"Milano","sequence":"additional","affiliation":[{"name":"Pediatric Hematology\/Oncology and Cell and Gene Therapy, IRCCS Bambino Ges\u00f9 Children\u2019s Hospital , Rome, 00165,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariantonietta Di","family":"Salvatore","sequence":"additional","affiliation":[{"name":"Medical Oncology, Universit\u00e0 Cattolica del Sacro Cuore, IRCCS, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4408-2373","authenticated-orcid":false,"given":"Angela","family":"Mastronuzzi","sequence":"additional","affiliation":[{"name":"Pediatric Hematology\/Oncology and Cell and Gene Therapy, IRCCS Bambino Ges\u00f9 Children\u2019s Hospital , Rome, 00165,","place":["Italy"]},{"name":"Department of Life Sciences and Public Health, Universit\u00e0 Cattolica del Sacro Cuore, Rome, 00168, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"key":"2026062614020711000_oyag134-B1","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1097\/01.pas.0000173232.22117.37","article-title":"Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature","volume":"29","author":"Folpe","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"2026062614020711000_oyag134-B2","doi-asserted-by":"publisher","first-page":"541626","DOI":"10.1155\/2012\/541626","article-title":"Malignant perivascular epithelioid cell neoplasm: risk stratification and treatment strategies","volume":"2012","author":"Bleeker","year":"2012","journal-title":"Sarcoma"},{"key":"2026062614020711000_oyag134-B3","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.anndiagpath.2015.06.003","article-title":"PEComa: morphology and genetics of a complex tumor family","volume":"19","author":"Thway","year":"2015","journal-title":"Ann Diagn Pathol"},{"key":"2026062614020711000_oyag134-B4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/path.2289","article-title":"Constant allelic alteration on chromosome 16p (TSC2 gene) in perivascular epithelioid cell tumour (PEComa): genetic evidence for the relationship of PEComa with angiomyolipoma","volume":"214","author":"Pan","year":"2008","journal-title":"J Pathol"},{"key":"2026062614020711000_oyag134-B5","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s12672-025-03270-z","article-title":"TSC2-mutated perivascular epithelioid cell tumor with partial response to mTOR inhibition: a case report and literature review","volume":"16","author":"Suo","year":"2025","journal-title":"Discov Oncol"},{"key":"2026062614020711000_oyag134-B6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.32074\/1591-951X-213","article-title":"The 2020 WHO classification of soft tissue tumours: news and perspectives","volume":"113","author":"Sbaraglia","year":"2021","journal-title":"Pathologica"},{"key":"2026062614020711000_oyag134-B7","doi-asserted-by":"publisher","first-page":"615","DOI":"10.2147\/CMAR.S351284","article-title":"Management strategies for adults with locally advanced, unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa): challenges and solutions","volume":"15","author":"Czarnecka","year":"2023","journal-title":"Cancer Manag Res"},{"key":"2026062614020711000_oyag134-B8","first-page":"4380","article-title":"Histopathologic characteristics and immunotypes of perivascular epithelioid cell tumors (PEComa)","volume":"12","author":"Bao","year":"2019","journal-title":"Int J Clin Exp Pathol"},{"key":"2026062614020711000_oyag134-B9","doi-asserted-by":"publisher","first-page":"210","DOI":"10.25259\/JLP-2023-9-5-(1941","article-title":"Prostatic perivascular epithelioid cell tumor: a rare entity and literature review","volume":"16","author":"Modi","year":"2024","journal-title":"J Lab Physicians"},{"key":"2026062614020711000_oyag134-B10","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/his.15304","article-title":"TFE3-rearranged nonmelanotic renal PEComa: a case series expanding their phenotypic and fusion landscape","volume":"85","author":"Agaimy","year":"2024","journal-title":"Histopathology"},{"key":"2026062614020711000_oyag134-B11","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/his.15087","article-title":"PEComa with ASPSCR1::TFE3 fusion: expanding the molecular genetic spectrum of TFE3-rearranged PEComa with an emphasis on overlap with alveolar soft part sarcoma","volume":"84","author":"Zhao","year":"2024","journal-title":"Histopathology"},{"key":"2026062614020711000_oyag134-B12","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1093\/jjco\/hyaf056","article-title":"PEComa-its clinical features, histopathology, and current therapy","volume":"55","author":"Izubuchi","year":"2025","journal-title":"Jpn J Clin Oncol"},{"key":"2026062614020711000_oyag134-B13","first-page":"5645","article-title":"Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors","volume":"62","author":"Kenerson","year":"2002","journal-title":"Cancer Res"},{"key":"2026062614020711000_oyag134-B14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00292-019-0612-5","article-title":"Complexity of PEComas\u202f: diagnostic approach, molecular background, clinical management","volume":"41","author":"Utpatel","year":"2020","journal-title":"Pathologe"},{"key":"2026062614020711000_oyag134-B15","doi-asserted-by":"publisher","first-page":"849004","DOI":"10.3389\/fonc.2022.849004","article-title":"Case report: a novel pathomechanism in PEComa by the loss of heterozygosity of TP53","volume":"12","author":"Butz","year":"2022","journal-title":"Front Oncol"},{"key":"2026062614020711000_oyag134-B16","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1097\/PAS.0000000000001119","article-title":"Uterine PEComas: a morphologic, immunohistochemical, and molecular analysis of 32 tumors","volume":"42","author":"Bennett","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"2026062614020711000_oyag134-B17","doi-asserted-by":"publisher","first-page":"212","DOI":"10.5146\/tjpath.2022.01592","article-title":"Malignant perivascular epithelioid cell tumor (PEComa) of the uterus as part of the hereditary cancer syndrome: a case diagnosed with multiple malignancies","volume":"39","author":"Cal\u0131skan","journal-title":"Turk J Pathol"},{"key":"2026062614020711000_oyag134-B18","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1097\/PAS.0000000000000389","article-title":"Dichotomy of genetic abnormalities in PEComas with therapeutic implications","volume":"39","author":"Agaram","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"2026062614020711000_oyag134-B19","doi-asserted-by":"publisher","first-page":"e692-7","DOI":"10.1016\/j.clgc.2020.04.004","article-title":"TFE3 gene rearrangement in perivascular epithelioid cell neoplasm (PEComa) of the genitourinary tract","volume":"18","author":"Vannucchi","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"2026062614020711000_oyag134-B20","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1038\/s41467-018-05862-6","article-title":"mTOR-dependent phosphorylation controls TFEB nuclear export","volume":"9","author":"Napolitano","year":"2018","journal-title":"Nat Commun"},{"key":"2026062614020711000_oyag134-B21","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"2026062614020711000_oyag134-B22","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.cub.2022.01.027","article-title":"Tuberous sclerosis complex gene products, tuberin and hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward rheb","volume":"32","author":"Tee","year":"2022","journal-title":"Curr Biol CB"},{"key":"2026062614020711000_oyag134-B23","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1083\/jcb.201307084","article-title":"Recruitment of folliculin to lysosomes supports the amino acid-dependent activation of Rag GTPases","volume":"202","author":"Petit","year":"2013","journal-title":"J Cell Biol"},{"key":"2026062614020711000_oyag134-B24","doi-asserted-by":"publisher","first-page":"11539","DOI":"10.1200\/JCO.2021.39.15_suppl.11539","article-title":"Deciphering the molecular landscape and the tumor microenvironment of perivascular epitheloid cell neoplasma (PEComa)","volume":"39","author":"Seeber","year":"2021","journal-title":"JCO"},{"key":"2026062614020711000_oyag134-B25","doi-asserted-by":"publisher","first-page":"3660","DOI":"10.1200\/JCO.21.01728","article-title":"nab-Sirolimus for patients with malignant perivascular epithelioid cell tumors","volume":"39","author":"Wagner","year":"2021","journal-title":"J Clin Oncol off J Am Soc Clin Oncol"},{"key":"2026062614020711000_oyag134-B26","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1097\/PAS.0000000000002218","article-title":"TFE3-Rearranged PEComa\/PEComa-like neoplasms: Report of 25 new cases expanding the clinicopathologic spectrum and highlighting its association with prior exposure to chemotherapy","volume":"48","author":"Argani","year":"2024","journal-title":"Am J Surg Pathol"},{"key":"2026062614020711000_oyag134-B27","doi-asserted-by":"publisher","first-page":"5227","DOI":"10.3390\/cancers13205227","article-title":"Natural history and treatment strategies of advanced PEComas: a systematic review","volume":"13","author":"Bourgmayer","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026062614020711000_oyag134-B28","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13569-016-0064-0","article-title":"Response to anti-PD1 therapy with nivolumab in metastatic sarcomas","volume":"6","author":"Paoluzzi","year":"2016","journal-title":"Clin Sarcoma Res"},{"key":"2026062614020711000_oyag134-B29","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMra055323","article-title":"The tuberous sclerosis complex","volume":"355","author":"Crino","year":"2006","journal-title":"N Engl J Med"},{"key":"2026062614020711000_oyag134-B30","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3390\/genes15030332","article-title":"The genetics of tuberous sclerosis complex and related mTORopathies: current understanding and future directions","volume":"15","author":"Man","year":"2024","journal-title":"Genes (Basel)"},{"key":"2026062614020711000_oyag134-B31","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/nrurol.2015.206","article-title":"Molecular genetics and clinical features of Birt-Hogg-Dub\u00e9 syndrome","volume":"12","author":"Schmidt","year":"2015","journal-title":"Nat Rev Urol"},{"key":"2026062614020711000_oyag134-B32","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/qjmed\/hcw109","article-title":"Novel folliculin (FLCN) mutation and familial spontaneous pneumothorax","volume":"110","author":"Zhu","year":"2017","journal-title":"QJM Mon J Assoc Physicians"},{"key":"2026062614020711000_oyag134-B33","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1097\/PAS.0000000000000133","article-title":"Perivascular epithelioid cell neoplasm (PEComa) of the gynecologic tract: clinicopathologic and immunohistochemical characterization of 16 cases","volume":"38","author":"Schoolmeester","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"2026062614020711000_oyag134-B34","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1002\/cncr.35277","article-title":"Pec-PRO: a new prognostic score from a series of 87 patients with localized perivascular epithelioid cell neoplasms (PEComas) treated with curative intent","volume":"130","author":"Gantzer","year":"2024","journal-title":"Cancer"},{"key":"2026062614020711000_oyag134-B35","first-page":"3663","article-title":"A retrospective study of patients with malignant PEComa receiving treatment with sirolimus or temsirolimus: the Royal Marsden Hospital experience","volume":"34","author":"Benson","year":"2014","journal-title":"Anticancer Res"},{"key":"2026062614020711000_oyag134-B36","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.3390\/jcm10102200","article-title":"Feasibility and long-term efficacy of PEComa treatment\u201420 years of experience","volume":"10","author":"Sobiborowicz","year":"2021","journal-title":"J Clin Med"},{"key":"2026062614020711000_oyag134-B37","doi-asserted-by":"publisher","first-page":"282","DOI":"10.4103\/0972-9941.166439","article-title":"Laparoscopic excision of infra-renal PEComa","volume":"11","author":"Bhanushali","year":"2015","journal-title":"J Minimal Access Surg"},{"key":"2026062614020711000_oyag134-B38","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.3390\/jcm10163705","article-title":"Efficacy of sirolimus treatment in PEComa-10 years of practice perspective","volume":"10","author":"\u015awitaj","year":"2021","journal-title":"J Clin Med"},{"key":"2026062614020711000_oyag134-B39","year":"2026"},{"key":"2026062614020711000_oyag134-B40","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1200\/JCO.23.02266","article-title":"Phase II trial of nab-Sirolimus in patients with advanced malignant perivascular epithelioid cell tumors (AMPECT): long-term efficacy and safety update","volume":"42","author":"Wagner","year":"2024","journal-title":"J Clin Oncol off J Am Soc Clin Oncol"},{"key":"2026062614020711000_oyag134-B41","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1200\/JCO.2009.25.2981","article-title":"Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors","volume":"28","author":"Wagner","year":"2010","journal-title":"J Clin Oncol off J Am Soc Clin Oncol"},{"key":"2026062614020711000_oyag134-B42","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/1477-7819-10-181","article-title":"Successful treatment with the mTOR inhibitor everolimus in a patient with perivascular epithelioid cell tumor","volume":"10","author":"Gennatas","year":"2012","journal-title":"World J Surg Oncol"},{"key":"2026062614020711000_oyag134-B43","doi-asserted-by":"publisher","first-page":"5295","DOI":"10.1158\/1078-0432.CCR-19-0288","article-title":"Role of chemotherapy, VEGFR inhibitors, and mTOR inhibitors in advanced perivascular epithelioid cell tumors (PEComas)","volume":"25","author":"Sanfilippo","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2026062614020711000_oyag134-B44","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41392-023-01608-z","article-title":"Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease","volume":"8","author":"Panwar","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"2026062614020711000_oyag134-B45","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","article-title":"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"381","author":"Bissler","year":"2013","journal-title":"Lancet Lond Engl"},{"key":"2026062614020711000_oyag134-B46","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1002\/ijc.27800","article-title":"Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: clinical and molecular correlates","volume":"132","author":"Dickson","year":"2013","journal-title":"Int J Cancer"},{"key":"2026062614020711000_oyag134-B47","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.3748\/wjg.v19.i10.1657","article-title":"PEComa of the colon resistant to sirolimus but responsive to doxorubicin\/ifosfamide","volume":"19","author":"Scheppach","year":"2013","journal-title":"World J Gastroenterol"},{"key":"2026062614020711000_oyag134-B48","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1477-7819-12-46","article-title":"Neoadjuvant sirolimus for a large hepatic perivascular epithelioid cell tumor (PEComa)","volume":"12","author":"Bergamo","year":"2014","journal-title":"World J Surg Oncol"},{"key":"2026062614020711000_oyag134-B49","doi-asserted-by":"publisher","first-page":"99","DOI":"10.4103\/0971-5851.133733","article-title":"Metastatic perivascular epithelioid cell tumor responding to mammalian target of rapamycin inhibition","volume":"35","author":"Ghosh","year":"2014","journal-title":"Indian J Med Paediatr Oncol"},{"key":"2026062614020711000_oyag134-B50","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.2147\/OTT.S85444","article-title":"The role of (18)F-FDG PET\/CT imaging in patient with malignant PEComa treated with mTOR inhibitor","volume":"8","author":"Sun","year":"2015","journal-title":"OncoTargets Ther"},{"key":"2026062614020711000_oyag134-B51","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/CAD.0000000000000324","article-title":"Neoadjuvant or adjuvant sirolimus for malignant metastatic or locally advanced perivascular epithelioid cell tumors: two case reports","volume":"27","author":"Batereau","year":"2016","journal-title":"Anticancer Drugs"},{"key":"2026062614020711000_oyag134-B52","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1080\/15384047.2016.1167290","article-title":"Combination targeted therapy of VEGFR inhibitor, sorafenib, with an mTOR inhibitor, sirolimus induced a remakable response of rapid progressive uterine PEComa","volume":"17","author":"Gao","year":"2016","journal-title":"Cancer Biol Ther"},{"key":"2026062614020711000_oyag134-B53","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jcrpr.2015.10.001","article-title":"Perivascular epithelioid cell tumor of the gastrointestinal tract","volume":"3","author":"Liu","year":"2016","journal-title":"J Cancer Res Pract"},{"key":"2026062614020711000_oyag134-B54","doi-asserted-by":"publisher","first-page":"6161","DOI":"10.21873\/anticanres.11208","article-title":"Treatment of advanced malignant uterine perivascular epithelioid cell tumor with mTOR inhibitors: single-institution experience and review of the literature","volume":"36","author":"Starbuck","year":"2016","journal-title":"Anticancer Res"},{"key":"2026062614020711000_oyag134-B55","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jcrpr.2017.04.001","article-title":"Huge soft tissue PEComa with aggressive lung and bone metastases","volume":"4","author":"Tang","year":"2017","journal-title":"J Cancer Res Pract"},{"key":"2026062614020711000_oyag134-B56","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jaapos.2017.05.022","article-title":"An orbital perivascular epithelioid cell tumor in a 7-year-old boy: case report and review of the literature","volume":"21","author":"Varan","year":"2017","journal-title":"J AAPOS"},{"key":"2026062614020711000_oyag134-B57","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1097\/PGP.0000000000000331","article-title":"Primary ovarian malignant PEComa: a case report","volume":"36","author":"Westaby","year":"2017","journal-title":"Int J Gynecol Pathol"},{"key":"2026062614020711000_oyag134-B58","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1097\/CAD.0000000000000634","article-title":"Prolonged activity and toxicity of sirolimus in a patient with metastatic renal perivascular epithelioid cell tumor: a case report and literature review","volume":"29","author":"Raimondi","year":"2018","journal-title":"Anticancer Drugs"},{"key":"2026062614020711000_oyag134-B59","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.pan.2019.05.459","article-title":"First pancreatic perivascular epithelioid cell tumor (PEComa) treated by mTOR inhibitor","volume":"19","author":"Gondran","year":"2019","journal-title":"Pancreatology"},{"key":"2026062614020711000_oyag134-B60","doi-asserted-by":"publisher","first-page":"NP14","DOI":"10.1177\/2150135116682452","article-title":"Cardiac perivascular epithelioid cell tumor: report of a child and review of the literature","volume":"11","author":"Rao","year":"2020","journal-title":"World J Pediatr Congenit Heart Surg"},{"key":"2026062614020711000_oyag134-B61","doi-asserted-by":"publisher","first-page":"1551663","DOI":"10.3389\/fonc.2025.1551663","article-title":"Case report: malignant perivascular epithelioid cell tumor with aggressive mediastinal invasion and pulmonary metastasis","volume":"15","author":"Leach","year":"2025","journal-title":"Front Oncol"},{"key":"2026062614020711000_oyag134-B62","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13000-023-01323-x","article-title":"A rare metastatic mesenteric malignant PEComa with TSC2 mutation treated with palliative surgical resection and nab-sirolimus: a case report","volume":"18","author":"Meredith","year":"2023","journal-title":"Diagn Pathol"},{"key":"2026062614020711000_oyag134-B63","doi-asserted-by":"publisher","first-page":"S180","DOI":"10.1016\/j.ygyno.2023.06.195","article-title":"Response to treatment with nab-sirolimus among patients with primary uterine PEComa: a sub analysis from AMPECT (1289)","volume":"176","author":"Palma","year":"2023","journal-title":"Gynecol Oncol"},{"key":"2026062614020711000_oyag134-B64"},{"key":"2026062614020711000_oyag134-B65","doi-asserted-by":"publisher","first-page":"128","DOI":"10.6323\/JCRP.2014.1.2.05","article-title":"Perivascular epithelioid cell tumors (PEComas) refractory to mTOR inhibitors","volume":"1","author":"Chen","year":"2014","journal-title":"J Cancer Res Pract"},{"key":"2026062614020711000_oyag134-B66","first-page":"3399","article-title":"Effective therapeutic intervention and comprehensive genetic analysis of mTOR signaling in PEComa: a case report","volume":"35","author":"Weeber","year":"2015","journal-title":"Anticancer Res"},{"key":"2026062614020711000_oyag134-B67","doi-asserted-by":"publisher","DOI":"10.4172\/2165-7920.1000880","article-title":"An aggressive case of malignant renal pecoma non-responsive to motor inhibition: a case report","volume":"6","author":"Binyamin","year":"2016","journal-title":"J Clin Case Rep"},{"key":"2026062614020711000_oyag134-B68","doi-asserted-by":"publisher","first-page":"4739","DOI":"10.3892\/ol.2016.5231","article-title":"Long-lasting stable disease with mTOR inhibitor treatment in a patient with a perivascular epithelioid cell tumor: a case report and literature review","volume":"12","author":"Flechter","year":"2016","journal-title":"Oncol Lett"},{"key":"2026062614020711000_oyag134-B69","doi-asserted-by":"publisher","first-page":"181","DOI":"10.15406\/jcpcr.2016.04.00142","article-title":"Malignant pervascular epitheloid cell tumor (PEComa), presenting as a large intra-abdominal mass in a young woman: a case report and review of literature","volume":"4","author":"Jamal Shaikh","year":"2016","journal-title":"J Cancer Prev Curr Res"},{"key":"2026062614020711000_oyag134-B70","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40001-017-0248-y","article-title":"Two cases of perivascular epithelioid cell tumor of the uterus: clinical, radiological and pathological diagnostic challenge","volume":"22","author":"Kwon","year":"2017","journal-title":"Eur J Med Res"},{"key":"2026062614020711000_oyag134-B71","doi-asserted-by":"publisher","first-page":"448","DOI":"10.14735\/amko2018448","article-title":"Dia-gnostic challenges and extraordinary treatment response in rare malignant PEComa tumor of the kidney","volume":"31","author":"Hu\u013eov\u00e1","year":"2018","journal-title":"Klin Onkol Cas Ceske Slov Onkol Spolecnosti"},{"key":"2026062614020711000_oyag134-B72","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.humpath.2017.11.016","article-title":"Malignant perivascular epithelioid cell tumor of the oropharynx with strong TFE3 expression mimicking alveolar soft part sarcoma: a case report and review of the literature","volume":"76","author":"Saluja","year":"2018","journal-title":"Hum Pathol"},{"key":"2026062614020711000_oyag134-B73","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12957-021-02462-5","article-title":"TFE3-associated perivascular epithelioid cell tumor with complete response to mTOR inhibitor therapy: report of first case and literature review","volume":"20","author":"Purwar","year":"2022","journal-title":"World J Surg Oncol"},{"key":"2026062614020711000_oyag134-B74","doi-asserted-by":"publisher","first-page":"797275","DOI":"10.3389\/fonc.2022.797275","article-title":"Uterine perivascular epithelioid tumors (PEComas) with lung metastasis showed good responses to mTOR and VEGFR inhibitors: a case report","volume":"12","author":"Sui","year":"2022","journal-title":"Front Oncol"},{"key":"2026062614020711000_oyag134-B75","doi-asserted-by":"publisher","first-page":"966818","DOI":"10.3389\/fonc.2022.966818","article-title":"Case report: Kidney perivascular epithelioid cell tumor treated with anti-VEGFR tyrosine kinase inhibitor and MTOR inhibitor","volume":"12","author":"Zhang","year":"2022","journal-title":"Front Oncol"},{"key":"2026062614020711000_oyag134-B76","doi-asserted-by":"publisher","first-page":"3334","DOI":"10.4240\/wjgs.v16.i10.3334","article-title":"Massive simultaneous hepatic and renal perivascular epithelioid cell tumor benefitted from surgery and everolimus treatment: a case report","volume":"16","author":"Yang","year":"2024","journal-title":"World J Gastrointest Surg"},{"key":"2026062614020711000_oyag134-B77","doi-asserted-by":"publisher","first-page":"206","DOI":"10.5603\/gpl.99247","article-title":"mTOR inhibitor in the treatment of TFE-positive advanced maligmnant PEComa of the uterus: a case report and literature review","volume":"96","author":"Zhong","year":"2025","journal-title":"Ginekol Pol"},{"key":"2026062614020711000_oyag134-B78","doi-asserted-by":"publisher","first-page":"4561","DOI":"10.1016\/j.radcr.2025.06.009","article-title":"PEComa with metastatic pulmonary embolism upon presentation: a case report","volume":"20","author":"Saliba","year":"2025","journal-title":"Radiol Case Rep"},{"key":"2026062614020711000_oyag134-B79","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s12328-024-02085-9","article-title":"A rare case of a malignant hepatic perivascular epithelioid cell tumor (PEComa) with aggressive progression following the relapse of renal pecoma despite everolimus therapy","volume":"18","author":"Kitagawa","year":"2025","journal-title":"Clin J Gastroenterol"},{"key":"2026062614020711000_oyag134-B80","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1080\/1750743X.2025.2558376","article-title":"Cracking the code: the emerging role of immune checkpoint inhibitors in PEComas","volume":"17","author":"Assi","year":"2025","journal-title":"Immunotherapy"},{"key":"2026062614020711000_oyag134-B81","doi-asserted-by":"publisher","first-page":"11553","DOI":"10.1200\/JCO.2025.43.16_suppl.11553","article-title":"Clinical activity of immune checkpoint blockade in advanced perivascular epithelioid cell neoplasms (PEComas): a retrospective single center study","volume":"43","author":"Reinhorn","year":"2025","journal-title":"JCO"},{"key":"2026062614020711000_oyag134-B82","doi-asserted-by":"publisher","first-page":"e013147","DOI":"10.1136\/jitc-2025-013147","article-title":"Multicenter phase II trial of ipilimumab and nivolumab in metastatic or unresectable perivascular epithelioid cell tumor (PEComa): a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609 (cohort 38)","volume":"13","author":"Patel","year":"2025","journal-title":"J Immunother Cancer"},{"key":"2026062614020711000_oyag134-B83","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s40425-018-0415-x","article-title":"Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy","volume":"6","author":"Lattanzi","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2026062614020711000_oyag134-B84","doi-asserted-by":"publisher","first-page":"e2200627","DOI":"10.1200\/PO.22.00627","article-title":"Metastatic malignant perivascular epithelioid cell tumors with microsatellite instability within Lynch syndrome successfully treated with anti-PD1 pembrolizumab","volume":"7","author":"Djerroudi","year":"2023","journal-title":"JCO Precis Oncol."},{"key":"2026062614020711000_oyag134-B85","doi-asserted-by":"publisher","first-page":"17588359241280541","DOI":"10.1177\/17588359241280541","article-title":"Metastatic perirectal PEComa treated by checkpoint inhibitor immunotherapy and multimodal treatment: case report and review of the literature","volume":"16","author":"R\u00e9mond","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"2026062614020711000_oyag134-B86","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1186\/s13256-021-02997-x","article-title":"Sustained response to pembrolizumab in recurrent perivascular epithelioid cell tumor with elevated expression of programmed death ligand: a case report","volume":"15","author":"McBride","year":"2021","journal-title":"J Med Case Reports"},{"key":"2026062614020711000_oyag134-B87","doi-asserted-by":"publisher","first-page":"e6969","DOI":"10.1097\/MD.0000000000006969","article-title":"Hepatic perivascular epithelioid cell tumor treated by transarterial embolization plus radiofrequency ablation: a case report and literature review","volume":"96","author":"Guan","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"2026062614020711000_oyag134-B88","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.juro.2015.04.081","article-title":"Transarterial embolization of angiomyolipoma: a systematic review","volume":"194","author":"Murray","year":"2015","journal-title":"J Urol"},{"key":"2026062614020711000_oyag134-B89","doi-asserted-by":"publisher","first-page":"e71754","DOI":"10.1002\/ccr3.71754","article-title":"Femoral PEComa treated with combined surgery and radiotherapy: a case report","volume":"14","author":"He","year":"2026","journal-title":"Clin Case Rep"},{"key":"2026062614020711000_oyag134-B90","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13014-018-0974-5","article-title":"Unresectable hepatic PEComa: a rare malignancy treated with stereotactic body radiation therapy (SBRT) followed by complete resection","volume":"13","author":"Kirste","year":"2018","journal-title":"Radiat Oncol Lond Engl"},{"key":"2026062614020711000_oyag134-B91","doi-asserted-by":"publisher","first-page":"iv506","DOI":"10.1093\/annonc\/mdu354.39","article-title":"1450P - Systemic therapy in perivascular epithelioid cell tumors (Pecoma)","volume":"25","author":"Hindi","year":"2014","journal-title":"Ann Oncol"},{"key":"2026062614020711000_oyag134-B92","author":"National Organization for Rare Disorders (NORD)","year":"2022"},{"key":"2026062614020711000_oyag134-B93","year":"2017"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag134\/67992733\/oyag134.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/7\/oyag134\/67992733\/oyag134.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/7\/oyag134\/67992733\/oyag134.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T18:02:15Z","timestamp":1782496935000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag134\/8644273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":93,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag134","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,4,8]]},"article-number":"oyag134"}}